What Balneum Plus Treats: Main Uses and Benefits

The primary therapeutic role of Balneum Plus is centered on providing supportive management and symptomatic relief for common skin conditions characterized by pronounced dryness and associated disruptive itching. It is generally used across domains where short-term symptomatic assistance is appropriate to help improve day-to-day comfort.

The preparation is for the management of symptoms associated with conditions such as pruritus, eczema, dermatitis, and scaling skin conditions.

Management of Persistent Cutaneous Pruritus (Itching)

This preparation is used in situations involving symptomatic discomfort where persistent itching represents symptoms that interfere with daily functioning. It is applied to ease challenging symptoms by offering symptomatic relief that helps to ease the urge to scratch. This therapeutic support generally contributes to improved comfort during phases where symptoms intensify, and may help patients cope more steadily with symptom fluctuations.

Supportive Therapy for Chronic Dry Skin Disorders

Balneum Plus is commonly used across conditions characterized by episodic or fluctuating symptom patterns, notably Eczema, Dermatitis, and scaling conditions like Psoriasis. The application helps address groups of symptoms that cluster into patterns requiring supportive management, assisting with maintaining functional stability and generally easing the overall symptomatic burden.

---

Quick Fact: Relief for Pronounced Dryness and Itching

This approach is primarily used when skin discomfort involves both moisture loss (xerosis) and persistent pruritus that disrupts daily comfort, and supports patients during episodes of heightened discomfort.

Eligibility Scope

The medicine is generally approved for use across all patient age groups, including adults, the elderly, and children. Regulatory information further states that the product may be used during pregnancy and the lactation period.

Contraindicated Populations

Use is contraindicated in patients with a known hypersensitivity to the active ingredients (Urea, Lauromacrogols) or any excipients, including known allergy to peanut or soya. The Cream formulation must not be used on acute erythroderma or acutely oozing or infected skin lesions. Similarly, the Bath Additive is contraindicated in patients with fresh pustular forms of Psoriasis.

Conditional Use and Restrictions

While use is widely permitted, specific conditional restrictions apply. The Cream must not be applied to the breasts immediately prior to breastfeeding. Furthermore, taking full baths with the Bath Additive requires prior medical consultation for individuals with conditions such as cardiac insufficiency, hypertension, severe infectious diseases, or major skin injuries. Official literature notes that urea-containing products in children may sometimes cause a temporary burning sensation on the skin.

Interactions with other medicines and products

Systemic Drug–Drug Interaction Status

Official regulatory documentation states that there are no known interactions when using this product with other systemic medicines, such as those taken orally or by injection. No co-administration of another medicinal product is formally designated as a contraindicated combination in the regulatory prescribing information.

Topical Exposure-Modifying Interaction

Regulatory documents classify the primary documented interaction as an exposure-modifying type involving other topical agents. The active component, urea, may increase the penetration through the skin barrier of co-administered topically applied medicines.

Medicines cited in regulatory documents that may be affected by this increased percutaneous absorption include topical corticosteroids, dithranol, and fluorouracil. The official restriction condition notes that this interaction occurs when the other topical medicines are used at the same time as the Balneum Plus preparation.

Pharmacodynamic Product Neutralization

A separate interaction is documented concerning certain cleansing substances. The additional use of non-medicinal substances, specifically soaps or syndets (synthetic detergents), is documented to neutralize the intended therapeutic effect of the Balneum Plus preparation. This functional constraint is officially noted in the regulatory material.

The Balneum Plus mechanism of action involves convergent effects derived from two primary components: soya oil and laureth-6.5. This pharmacodynamic profile addresses both epidermal barrier function and peripheral sensory signaling.

The soya oil component is topically incorporated into the intercellular lipid matrix of the stratum corneum, which is the outermost layer of the epidermis. This incorporation restores and reorganizes the compromised lipid lamellae, resulting in a quantifiable decrease in transepidermal water loss (TEWL). This physiological consequence facilitates the retention and uptake of water and essential lipids within the skin structure.

The second component, laureth-6.5, exerts an effect on peripheral sensory nerve conduction. It acts to modulate the activity of voltage-gated sodium channels located on primary afferent neurons. This biophysical interaction decreases the rate and intensity of nerve impulse propagation, thereby modulating afferent signaling from the dermal-epidermal junction. The combined physiological consequence is a dual action on epidermal hydration and peripheral sensory transduction.

Administration Guidelines for Balneum Plus

Balneum Plus is available in two approved dosage forms—a Cream and a Liquid Bath Additive (Topical Solution)—both strictly intended for topical application. The administration protocol differs based on the formulation being used, following specific, standardized instructions.

Dosing and Frequency

The Cream formulation is applied topically to the affected skin areas twice a day.

For the Liquid Bath Additive, the standard regimen is immersion at least three times per week for adults and children, with daily use recommended for infants and babies.

• Adult Full Bath Dose: Typically 20 ml (1 capful) is added, which may be increased to two or three times the amount (up to 60 ml) for very dry conditions.
• Child/Baby Bath Dose: 1/4 of a capful (approx 5 ml) is used for children's baths.

Preparation and Procedural Constraints

Before adding the Liquid Bath Additive, the bottle must be shaken well to ensure the ingredients are mixed. The liquid is poured into the bath as the water fills and is mixed to achieve even distribution.

Special Procedural Conditions:

• Temperature and Duration: Bath water temperature must not exceed 36 °C, with a lower temperature (approx 32 °C) recommended specifically for treating itching. The bath duration is constrained to a minimum of 10 minutes and a maximum of 20 minutes.
• Post-Application: After bathing or showering, the skin must be gently patted dry with a towel. Vigorously wiping or rubbing the skin is specified as reducing the therapeutic effect.

Connection to the overall use protocol: Established protocols define distinct parameters for the cream and bath additive, specifying the route, frequency, and environmental constraints such as temperature and duration. The duration of therapy for both forms is not fixed but is dependent on the course of the condition, requiring continuous supervision.

Research Evidence / Overview of Studies for Balneum Plus

Evidence for Use in Broad Dry Skin Disorders and Eczema

Research exploring how symptoms change over time for conditions like dry skin (xerosis), eczema, and related scaling disorders includes observational studies and post-marketing surveys. These study types were applied in studies examining patient-reported experiences in observational settings evaluating daily-life functioning. Research explored outcomes related to physical discomfort, such as changes in the skin's texture (like roughness and scaling) and measures of pruritus (itching). These studies included heterogeneous patient groups encompassing both adult and pediatric patients with varying symptom burdens.

Studies report how symptoms evolved in the observed populations during the defined time intervals of the research. Findings describe patterns observed in the studies related to changes in perceived discomfort and visible aspects of the skin. Because this research often relies on patient self-reporting and is non-controlled, the quality of the evidence varies, and the certainty remains Moderate for this context.

---

Evidence for Use in Pruritus Associated with Systemic Disease

Specific research, used in studies examining symptom intensity in the setting of pruritus associated with chronic kidney disease (CKD-aP), was evaluated in a single, short-term Randomized Controlled Trial (RCT). This trial represents a high standard of methodological rigor among the available research. Research explored patient-reported outcomes describing perceived discomfort, with a primary focus on measuring the intensity of the itching itself. Outcomes reflecting daily functioning or activity level, such as sleep disruption, were also monitored. The trial population was restricted to a specific patient group of adult haemodialysis patients who were experiencing chronic itching.

The controlled trial measured the change in itch intensity after the four-week period. Research highlights changes measured during the study period; however, the findings reported that the measured change in itching did not establish a difference when comparing the studied product to an emollient control cream.

---

Research Gaps and What Remains Uncertain

The overall evidence for Balneum Plus contributes to understanding symptom patterns, but it also highlights key areas where more research is ongoing. Key limitations include the fact that follow-up durations were limited across the research base, offering little information about long-term use. Additionally, comparative evidence is lacking when considering how this dual-action product compares to other widely available single-action emollients in controlled, blinded settings outside of the single CKD-aP trial. Research does not determine whether an individual will respond similarly to the group patterns observed, as study results reflect the specific conditions under which they were conducted. Data for certain groups remain insufficient, such as dedicated research on pregnant or complex comorbid conditions.

Key Studies & References

1. Results of a Postmarketing Drug Monitoring Survey With a Polidocanol-Urea Preparation for Dry, Itching Skin

Common questions about Balneum Plus (FAQ)

Q: Does Balneum Plus contain any steroids?

According to official product information, the active ingredients in Balneum Plus are Urea and Lauromacrogol (Polidocanol).

Corticosteroids are not listed as active components in either the cream or the bath additive formulation. This is based purely on the chemical composition described in the regulatory documents.

Q: Are there any known long-term side effects from using Balneum Plus?

Official safety documentation details adverse reactions that have been observed during clinical and post-marketing periods. However, studies referenced in the official information are noted to have limited follow-up durations.

This means long-term safety information extending far beyond the defined research periods is not fully characterized or established.

Q: Can Balneum Plus be used on the face?

The official warnings for Balneum Plus emphasize that contact with the eyes and mucous membranes must be avoided due to the risk of irritation.

While the product is generally approved for topical use, there is no specific guidance provided regarding its application to the face in regulatory documents.

Q: Can I use Balneum Plus alongside prescription eczema creams?

Regulatory documents indicate that the urea component of Balneum Plus may increase the penetration through the skin of other topically applied medicines. This specifically includes topical corticosteroids, which are commonly used for eczema.

The official prescribing information flags this potential exposure-modifying interaction.

Q: What does the 'plus' component in Balneum Plus actually mean for the patient?

The 'Plus' in the name refers to the product's dual-action composition, which contains two principal active ingredients. In addition to the hydrating component, Urea, the formulation includes Lauromacrogol (Polidocanol), which provides a separate antipruritic (anti-itch) effect.

This dual composition provides an integrated approach to managing both dryness and itching.

Q: Is Balneum Plus effective for dry skin not caused by eczema?

Official product information states that the product is indicated for the management of dry skin conditions known as xerosis (general dry skin) and related scaling disorders, in addition to eczema.

Regulatory documents classify it as an emollient and antipruritic combination, indicating its use is targeted for when both dryness and persistent itching are present.

Q: Why do some health sites call Balneum Plus a bath oil?

The liquid formulation is officially designated as an Oleaginous Liquid Bath Additive or Topical Solution in regulatory documents.

Because the liquid contains oils and is designed to be added to bath water, the common descriptive term 'bath oil' is often used to refer to this type of product by patients and health sites.

Q: Is Balneum Plus available without a prescription?

Balneum Plus is typically classified as a Pharmacy Medicine (P) or similar designation in regulatory systems.

This means it may be purchased without a medical prescription, but its sale is generally restricted to a licensed pharmacy and is subject to the pharmacist's discretion.

Q: Is Balneum Plus recommended for allergic skin reactions?

The official safety labeling states that the product is contraindicated—meaning it should not be used—in cases of known hypersensitivity (severe allergy) to any component.

It is not indicated or labeled as a treatment for acute allergic skin reactions.

Q: Has Balneum Plus been studied in clinical trials?

Regulatory documents confirm that the evidence base for Balneum Plus includes references to both controlled research methods, such as Randomized Controlled Trials (RCTs), and observational studies.

This research was conducted to evaluate symptom patterns and the physiological effects of the product.

Q: How is Balneum Plus classified by drug regulatory bodies?

Official drug regulatory bodies classify Balneum Plus as a dermatological preparation.

More specifically, its composition leads to its classification as an emollient and antipruritic combination, highlighting its dual purpose for skin hydration and itch relief.

Q: Is there a difference in strength between the different Balneum Plus product types?

The Cream and the Liquid Bath Additive are chemically distinct formulations, as noted in the official composition documents.

While both product types contain the two active components (Urea and Lauromacrogol), their excipients and the resulting concentration of active ingredients are different, resulting in different instructions for use in the respective product information.

Q: Why do some people find Balneum Plus irritates their eyes?

The official safety warning requires that contact with the eyes and mucous membranes must be avoided.

This warning is included because the product's ingredients can cause local irritation or discomfort upon contact with these sensitive areas.

Q: Can Balneum Plus be used by people with nut allergies?

Official regulatory documentation explicitly lists a known allergy to peanut or soya as a contraindication for using Balneum Plus.

This is because soya oil is used as an excipient (a non-active ingredient) in the formulation, and the product is therefore contraindicated for individuals with a known allergy to these components.

Q: What is the expected duration of treatment with Balneum Plus?

Official labeling states that the duration of therapy with Balneum Plus is not fixed by the label.

Instead, the length of use is determined by the course of the patient's condition and requires ongoing supervision from a healthcare professional.

Q: Is Balneum Plus known to cause drowsiness?

The official list of documented adverse reactions for Balneum Plus does not include drowsiness or any other specific central nervous system (CNS) effects.

Furthermore, the official section on effects on driving and operating machinery does not list any warnings related to sedation or impaired consciousness.

How to Store and Dispose of Balneum Plus?

Storage Requirements

Balneum Plus Cream and Bath Additive must be stored below 25 C and should not be exposed to temperatures above this limit. The product must be kept out of the sight and reach of children for safety.

• Temperature Constraint: Store below 25 C.
• Child Protection: Keep out of sight and reach of children.
• Packaging Rule: The Bath Additive should be stored in its original pack.
• Stability: Do not use the medicine after the expiration date (EXP) shown on the packaging.

Disposal Instructions

Expired or unused Balneum Plus should not be disposed of via wastewater or household waste. Disposal must be completed in accordance with local requirements to protect the environment. Patients should consult a pharmacist for guidance on proper pharmaceutical waste disposal.